



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/527,294	02/22/2006	James P. Beck	02-730-B6	9625
20306 7590 08/06/2008 MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE 32ND FLOOR CHICAGO, IL 60606				
EXAMINER				
ROBINSON, BINTA M				
ART UNIT		PAPER NUMBER		
1625				
MAIL DATE		DELIVERY MODE		
08/06/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/527,294

Applicant(s)

BECK ET AL.

Examiner

BINTA M. ROBINSON

Art Unit

1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-20 is/are pending in the application.
- 4a) Of the above claim(s) 18 is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-16, 19 and 20 is/are rejected.
- 7) ☒ Claim(s) 17 is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-946)
- 3) ☐ Information Disclosure Statement(s) (PTO/SF/ICE)
Paper No(s)/Mail Date ____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date ____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: ____

Detailed Action

The examiner notes that the applicant has elected the Group I invention which is drawn to claims 1-17 and 19-20 as well as the elected species of example 5 found at page 82. Claim 18 is withdrawn from examination because it is nonelected.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1, 4,5-13 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 5-11, 13-17, 30-32 of copending Application No. 10532285, US PG Pub 20060148803. Although the conflicting claims are not identical, they are not patentably distinct from each other because the process of a using the instant genus of compounds which overlaps in subject matter with the instant genus of compounds claimed.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.


The copending application teaches a process of using a genus of compounds of formula I. At page 2, see claim 1. The difference between the prior art and the instantly application is the teaching of a process of using a genus of compounds which overlaps in subject matter with the instant genus of compounds. Additionally, it is also long been the rule that discovery of a new use of a product or process that is structurally or operationally identical or similar to a known product will not support a claim for the product. Accordingly, the compounds are deemed unpatentable therefrom in the absence of a showing of unexpected results for the claimed compounds over those of the generic prior art compounds that are used as to treat Alzheimer's disease.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 5-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bennett et. al in view of Patani et. al..Bennett et. al. teaches the compound of formula H. At columns 9-10, see the compound of formula H,

Art Unit: 1625



The difference between the prior art compound and the instantly claimed compounds is teaching of Y moiety in the Rn group as equal to pyridyl in the prior art, whereas it is equal to phenyl in the instant compounds. Patani teaches that phenyl is a bioisosteric replacement of pyridyl. See Part II, part E of Patani et. al. Since the prior art compound has a use, it would have been obvious to one of ordinary skill in the art to modify the prior art compound to the synthesize the bioisostere of the prior art compound. Accordingly, the compounds are deemed unpatentable therefrom in the absence of a showing of unexpected results for the claimed compounds over those of the generic prior art compounds.

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. Claims 1-16, 20 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The specification does not enable any skilled pharmacologist or physician to use the invention commensurate in scope with these claims. The

factors to be considered in making an enablement rejection have been summarized below.

There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is "undue". These factors include 1) the breadth of the claims, 2) the nature of the invention, 3) the state of the prior art, 4) the level of one of ordinary skill, 5) the level of predictability in the art 6) the amount of direction provided by the inventor 7) the existence of working examples, and 8) the quantity of experimentation needed to make or use the invention based on the content of the disclosure. In *re Wands*, 858 F. 2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).


a) Determining if any of the particular claimed compounds would be active would require synthesis of the substrate and subjecting it to testing with Applicants' inhibition of A Beta production in Human patients assay, inhibition of Beta-Secretase in Animals Models of Alzheimer's Disease Assay, Inhibition of Beta-Secretase Activity-Cellular Assay, Assays using Synthetic Oligopeptide-Substrates, Assays regarding Beta-Secretase Inhibition, Free Inhibition Assay Utilizing a Synthetic APP substrate, and Enzyme Inhibition Assay. Considering the large number of compounds to be made this is a large quantity of experimentation. b) The direction concerning the claimed compounds is found in

at pages 81-91, which merely states Applicants' intent to make such compounds.

c) In the instant case, there are no working examples, where any of the actual compounds used in the assays noted above are - disclosed. Additionally, no experimental data for the assays is disclosed.

d) The nature of the invention is inhibition of Beta-secretase mediated cleavage of APP and treatment of Alzheimer's disease, the treatment and prevention or delay of the onset of Alzheimer's disease, and the treatment of mild cognitive impairments with Applicants' compounds. This involves physiological activity. The nature of the invention requires an understanding of the beta-secretase, the binding activity of small ligands to that receptor, and the ability of those compounds to inhibit beta-secretase. In view of the unpredictability of receptor binding activity and claimed divergent substituents with varied polarity, size, and polarisability, the skilled physician would indeed question the inclusion of such diverse rings, commensurate in scope with these claims. Also see the MPEP § 2164.03 for enablement requirements in the structure sensitive arts of pharmacology and medicinal chemistry.

e) There is no reasonable basis for the assumption that the myriad of




compounds embraced by the formula

will all share the

same biological and chemical properties, since nonobvious moieties are claimed such as for example, R₁ equal to any aryl ring or any heteroaryl ring. The diverse claimed compounds, are chemically non-equivalent and there is no basis in the prior art for assuming in the non-predictable art of pharmacology that structurally dissimilar compounds will have such activity, *In re Surrey* 151 USPQ 724 (compounds actually tested which demonstrated the asserted psychomotor stimulatory and anti-convulsant properties were those having the 3,4-dichlorophenyl substituent at the 2-position on the thiazolidone nucleus not sufficient for enablement of any heterocyclic radical at the same position). *In re Fouché*, 169 USPQ 429 at 434 (a Markush group including both aliphatic and heterocyclic members not enabled for the use of those compounds within the claim having heterocyclic moieties.) *In re CAVALLITO AND GRAY*, 127 USPQ 202 (claims covering several hundred thousand possible compounds, of which only thirty are specifically identified in appellants' application, not enabled unless all of the thirty specific compounds disclosed had equal hypotensive potency because

that fact would strongly indicate that the potency was derived solely from the basic structural formula common to all of them. A wide variation in such potency would suggest that it was due in part to the added substituents and might be eliminated or even reversed by many of the possible substituents which had not been tried.)

f) The artisan using Applicants' invention to treat diseases with the claimed compounds would be a physician with a MD degree and several years of experience. He would be unaware of how to predict *a priori* how a changing a heterocyclic ring would affect biological activity. In view of the divergent rings with varied basicity, steric hindrance, and polarisability, the skilled physician would indeed question the inclusion of such fused rings, commensurate in scope with these claims. g) Physiological activity, is well-known to be unpredictable, *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) (contrasting mechanical and electrical elements with chemical reactions and physiological activity). See also *In re Wright*, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993); *In re Vaeck*, 947 F.2d 488, 496, 20 USPQ2d 1438, 1445 (Fed. Cir. 1991). h) The breadth of the claims includes all of millions of compounds of




formula

. Thus, the scope is very broad. The present

claims embrace various heterocyclic radicals, heteroaryl radicals, and alicyclic radicals, which are not art-recognized as equivalent. The specific compounds made are not adequately representative of the compounds embraced by the extensive Markush groups instantly claimed.

MPEP 2164.01(a) states, "A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. *In re Wright*, 999 F.2d 1557,1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)." That conclusion is clearly justified here. Thus, undue experimentation will be required to practice Applicants' invention.


Claim 19 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for making the compounds of formula



with R₂₀ equal to H, R₁ equal to 2, 4-difluorobenzyl, X equal to oxygen, R₂ and R₃ equal to hydrogen, R_c equal to p-ethylphenyl, R_n equal to -C(O)-(CRR')₀-6R₁₀₀, wherein R₁₀₀ is equal to phenyl, substituted with -(CH₂)₀-4-CO-N105R'105, wherein R₁₀₅ and R'105 are equal to n-propyl, or -

Art Unit: 1625

(CH₂)₀₋₄R₁₁₀, or -(CH₂)₀₋₄R₁₂₀, wherein R₁₀₀ is equal to C₁-C₁₀ alkyl, and R₁₂₀ is heteroaryl of 1,3-oxazol-2-yl, 1,3-thiazol-2-yl, R₁₀₀ is C₁-C₁₀ alkyl, X' is -NR₄₋₆, and Y is C₆-C₁₀ aryl, and R₄₋₆ is H, does not reasonably provide




enablement for making the compounds of formula , with

the radicals above equal to all other claimed moieties other than those noted above.

The specification does not enable any skilled pharmacologist or physician to use the invention commensurate in scope with these claims.

There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is "undue". These factors include 1) the breadth of the claims, 2) the nature of the invention, 3) the state of the prior art, 4) the level of one of ordinary skill, 5) the level of predictability in the art 6) the amount of direction provided by the inventor 7) the existence of working examples, and 8) the quantity of experimentation needed to make or use the invention based on the content of the disclosure. In *re Wands*, 858 F. 2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

a) Determining if any of the particular claimed compounds of formula




with the radicals equal to all other claimed moieties

other than those noted above would be active would require synthesis of the substrate and subjecting it to testing with Applicants' inhibition of A Beta production in Human patients assay, inhibition of Beta-Secretase in Animals Models of Alzheimer's Disease Assay, Inhibition of Beta-Secretase Activity-Cellular Assay, Assays using Synthetic Oligopeptide-Substrates, Assays regarding Beta-Secretase Inhibition, Free Inhibition Assay Utilizing a Synthetic APP substrate, and Enzyme Inhibition Assay. Considering the large number of compounds to be made this is a large quantity of experimentation. b) The direction concerning the claimed compounds is found in at pages 81-91, which merely states Applicants' intent to make such compounds. c) In the instant case, there are no working examples, where any of the actual compounds used in the assays noted above are - disclosed. Additionally, no experimental data for the assays is disclosed.

d) The nature of the invention is inhibition of Beta-secretase mediated cleavage of APP and treatment of Alzheimer's disease, the treatment and

prevention or delay of the onset of Alzheimer's disease, and the treatment of mild cognitive impairments with Applicants' compounds. This involves physiological activity. The nature of the invention requires an understanding of the beta-secretase, the binding activity of small ligands to that receptor, and the ability of those compounds to inhibit beta-secretase. In view of the unpredictability of receptor binding activity and claimed divergent substituents with varied polarity, size, and polarisability, the skilled physician would indeed question the inclusion of such diverse rings, commensurate in scope with these claims. Also see the MPEP § 2164.03 for enablement requirements in the structure sensitive arts of pharmacology and medicinal chemistry.

e) There is no reasonable basis for the assumption that the myriad of




compounds embraced by the formula will all share the same biological and chemical properties, since nonobvious moieties are claimed such as for example, R₁ equal to any aryl ring or any heteroaryl ring. The diverse claimed compounds, are chemically non-equivalent and there is no basis in the prior art for assuming in the non-predictable art of pharmacology that structurally dissimilar compounds will have such activity, *In re Surrey* 151 USPQ 724

(compounds actually tested which demonstrated the asserted psychomotor stimulatory and anti-convulsant properties were those having the 3,4-dichlorophenyl substituent at the 2-position on the thiazolidone nucleus not sufficient for enablement of any heterocyclic radical at the same position). *In re Fouche*, 169 USPQ 429 at 434 (a Markush group including both aliphatic and heterocyclic members not enabled for the use of those compounds within the claim having heterocyclic moieties.) *In re CAVALLITO AND GRAY*, 127 USPQ 202 (claims covering several hundred thousand possible compounds, of which only thirty are specifically identified in appellants' application, not enabled unless all of the thirty specific compounds disclosed had equal hypotensive potency because that fact would strongly indicate that the potency was derived solely from the basic structural formula common to all of them. A wide variation in such potency would suggest that it was due in part to the added substituents and might be eliminated or even reversed by many of the possible substituents which had not been tried.)

f) The artisan using Applicants' invention to treat diseases with the claimed compounds would be a physician with a MD degree and several years of experience. He would be unaware of how to predict *a priori* how a changing a heterocyclic ring would affect biological activity. In view of the divergent rings with varied basicity, steric hindrance, and polarisability, the skilled physician

would indeed question the inclusion of such fused rings, commensurate in scope with these claims. g) Physiological activity, is well-known to be unpredictable, *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) (contrasting mechanical and electrical elements with chemical reactions and physiological activity). See also *In re Wright*, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993); *In re Vaeck*, 947 F.2d 488, 496, 20 USPQ2d 1438, 1445 (Fed. Cir. 1991). h) The breadth of the claims includes all of millions of compounds of



formula $\text{R}_1\text{R}_2\text{R}_3$. Thus, the scope is very broad. The present claims embrace various heterocyclic radicals, heteroaryl radicals, and alicyclic radicals, which are not art-recognized as equivalent. The specific compounds made are not adequately representative of the compounds embraced by the extensive Markush groups instantly claimed.

MPEP 2164.01(a) states, “A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. *In re Wright*, 999 F.2d 1557,1562, 27 USPQ2d 1510, 1513 (Fed.

Cir. 1993).” That conclusion is clearly justified here. Thus, undue experimentation will be required to practice Applicants' invention.

3. Claim 17 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The elected species is allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Binta M. Robinson whose telephone number is (571) 272-0692. The examiner can normally be reached on M-F (9:30-6:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Janet Andres can be reached on 571-272-0670.

A facsimile center has been established. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machine are (703)308-4242, (703)305-3592, and (703)305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571)272-1600.

/Janet L. Andres/

Supervisory Patent Examiner, Art Unit 1625